Clinical significance and prevalence of T315I mutation in Imatinib Mesylate resistance in Indian Chronic Myeloid Leukemia patients. (First study from India)

被引：0
|
作者：
Mir, Rashid [1 ]
Sazawal, S. [1 ]
Chobey, R. [1 ]
Bohra, B. [1 ]
Bharti, S. [1 ]
Ravi, K. [1 ]
Pravas, M. [1 ]
Mehraj, Q. [2 ]
Yasrib, M. [2 ]
Mudasir, T. [2 ]
Shyam, R. [1 ]
Saxena, R. [1 ]
机构：
[1] All India Inst Med Sci, Dept Haematol, New Delhi, India
[2] Univ Kashmir, Srinagar 190006, Jammu & Kashmir, India
来源：
JOURNAL OF MEDICAL GENETICS | 2008年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [1] IMPACT OF HIGH SENSITIVE DETECTION, INCIDENCE AND SIGNIFICANCE OF T315I MUTATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE (FIRST STUDY FROM INDIA)
    Ab, R. M.
    Saxena, R.
    Sazawal, S.
    Bohra, B.
    Chobey, R.
    Mishra, P.
    Chopra, A.
    Saxena, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 575 - 575
  • [2] Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Kazemi, Ahmad
    Ostadali, Mohammadreza
    Nadali, Fatemeh
    Rostami, Shahrbano
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    HEMATOLOGY, 2013, 18 (03) : 158 - 162
  • [3] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    Jabbour, Elias
    Kantarjian, Hagop
    Jones, Dan
    Breeden, Megan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge
    BLOOD, 2008, 112 (01) : 53 - 55
  • [4] Characteristics and outcome of patients with chronic myeloid leukemia (CML) and T315I mutation following failure of imatinib mesylate therapy
    Jabbour, Elias
    Kantarjiah, Hagop
    Jones, Dan
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 577A - 578A
  • [5] METABOLIC CHARACTERISTICS OF IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA WITH T315I MUTATION
    Heo, J. Y.
    Han, J.
    Ryu, M. J.
    Jang, Y.
    Kim, S. J.
    Kim, J.
    Lee, M. J.
    Kweon, G. R.
    HAEMATOLOGICA, 2015, 100 : 432 - 432
  • [6] The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation
    Chen Chen
    Na Xu
    Wu WanEr
    Liu Liang
    Xuan Zhou
    Huang JiXian
    Yin Changxin
    Rui Cao
    Liu, Qifa
    Liu Xiaoli
    BLOOD, 2018, 132
  • [7] Clinical significance of T315I ABL kinase domain mutation detection in patients resistant to imatinib mesylate therapy
    Horvat, Ivana
    Antolic, Margareta Radic
    Zadro, Renata
    Sertic, Dubravka
    Labar, Boris
    BIOCHEMIA MEDICA, 2010, 20 (01) : 75 - 81
  • [8] Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
    Mardziah, M.
    Salwati, S.
    Azlin, I
    Hafiza, A.
    Farisah, Noor A. R.
    Noraesah, M.
    Tumian, N. R.
    Wong, C. L.
    Azma, R. Z.
    MEDICINE AND HEALTH-KUALA LUMPUR, 2019, 14 (01): : 145 - 156
  • [9] Novel kinase inhibitor for imatinib-resistant chronic myeloid leukemia with T315I mutation
    Hong, Soon-Sun
    Kim, Soo Jung
    Jung, Kyung Hee
    Yan, Hong Hua
    Fang, Zhenghuan
    Lim, Joo Han
    Ryu, Jeong Seon
    CANCER RESEARCH, 2015, 75
  • [10] Asciminib Management in Chronic Myeloid Leukemia (CML) Patients With T315I Mutation
    Kuzmina, Elena
    Lomaia, Elza
    Morozova, Elena
    Chelysheva, Ekaterina
    Shukhov, Oleg
    Petrova, Anna
    Chitanava, Tamara
    Vlasova, Yulia
    Sbityakova, Evgenia
    Makarova, Tayana
    Nemchenko, Irina
    Bykova, Anastasiya
    Gurianova, Margarita
    Julhakyan, Hunan
    Kokhno, Alina
    Turkina, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S334 - S334
12345